References
- US Food and Drug AdministrationIs it really FDA Approved?2202009 Available from: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm047470.htm. Accessed Apr 5, 2011.
- O’NeillRTA perspective on characterizing benefits and risks derived from clinical trials: can we do more?Drug Inf J2008423235245
- Roth-ClineMDClinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugsCirculation2006113182253225916684875
- AvornJEvaluating drug effects in the post-Vioxx world: there must be a better wayCirculation2006113182173217616684873
- FurbergCDLevinAAGrossPAShapiroRSStromBLThe FDA and drug safety: a proposal for sweeping changesArch Intern Med2006166181938194217030825
- GuoJJPandeySDoyleJBianBLisYRaischDWA review of quantitative risk-benefit methodologies for assessing drug safety and efficacy – report of the ISPOR risk-benefit management working groupValue Health201013565766620412543
- GarrisonLPJrTowseABresnahanBWAssessing a structured, quantitative health outcomes approach to drug risk-benefit analysisHealth Aff (Millwood)200726368469517485745
- GarrisonLPRegulatory benefit-risk assessment and comparative effectiveness research: strangers, bedfellows, or strange bedfellows?Pharmacoeconomics2010281085586520831293
- TowseANet clinical benefit: the art and science of jointly estimating benefits and risks of medical treatmentValue Health201013Suppl 1S30S3220618793
- SchwartzLMWoloshinSWelchHGUsing a drug facts box to communicate drug benefits and harms: two randomized trialsAnn Intern Med2009150851652719221371
- ClaxtonKPosnettJAn economic approach to clinical trial design and research priority-settingHealth Econ1996565135249003938